Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 18/20 | 1.00 |
| ▸ | JAK3 | P52333 | 18/20 | 1.00 |
| ▸ | JAK1 | P23458 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6524827 | 1.00 | JAK2 (1.00) | JAK2JAK3JAK1 | |
| SCHEMBL6523673 | 0.88 | JAK2 (1.00) | JAK2JAK3JAK1 | |
| SCHEMBL6523682 | 0.88 | JAK2 (1.00) | JAK2JAK3JAK1 | |
| SCHEMBL6519542 | 0.88 | JAK2 (1.00) | JAK2JAK3JAK1 | |
| SCHEMBL6519537 | 0.88 | JAK2 (1.00) | JAK2JAK3JAK1 | |
| SCHEMBL6523456 | 0.87 | JAK2 (1.00) | JAK2JAK3JAK1 | |
| SCHEMBL6523450 | 0.87 | JAK2 (1.00) | JAK2JAK3JAK1 | |
| SCHEMBL6519487 | 0.85 | JAK2 (1.00) | JAK2JAK3JAK1 | |
| SCHEMBL6519499 | 0.85 | JAK2 (1.00) | JAK2JAK3JAK1 | |
| SCHEMBL6519531 | 0.81 | JAK2 (1.00) | JAK2JAK3JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8618103-B2 | Inhibitors of JAK | HOFFMANN-LA ROCHE INC. (US) | 2013-12-31 | — | — | US | claimed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | claimed |
| US-8618103-B2 | Inhibitors of JAK | HOFFMANN-LA ROCHE INC. (US) | 2013-12-31 | — | — | US | disclosed |
| WO-2011029804-A1 | INHIBITORS OF JAK | F. HOFFMANN-LA ROCHE AG (CH) | 2011-03-17 | — | — | WO | disclosed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | disclosed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | disclosed |
| US-20110059118-A1 | INHIBITORS OF JAK | DE VICENTE FIDALGO JAVIER | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059118-A1 | INHIBITORS OF JAK | JAK1, JAK3, JAK2 | JAK2 3/4885JAK3 2/4885JAK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.